Department of Health & Human Services, National Institutes of Health. Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research: Comprehensive Report: Tracking of Human Subjects Research as Reported in the Fiscal Year 2003 and Fiscal Year 2004. NIH Office of Policy for Extramural Research Adm., 2005.
*
Brittle, Christine, and Chloe E. Bird [Uncommon Insights]; Department of Health & Human Services (HHS) Office of Research on Women's Health (ORWH) [produced for]. Literature Review on Effective Sex- and Gender-Based Systems/Models of Care. Arlington, VA: Uncommons Insights, 2007. Table of Contents.
*
Legato, Marianne J. The Food and Drug Administration: An Agency Under Siege. Gender Medicine [Editorial]. 5(3):197-199. Publisher abstract. [Not government document, but important and about government agency]
*
National Institutes of Health. Agenda for Research on Women’s Health for the 21st Century: A Report of the Task Force on the NIH Women’s Health Agenda for the 21st Century: Executive Summary. Vol. 1. [Bethesda, MD]: National Institutes of Health, Office of the Director, Office of Research on Women's Health, 1999. NIH publication no. 99-4385-90. (Note: There are links from the Publications section under Research Agenda to the complete 8 volume report.)
*
National Institutes of Health. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Notices. Federal Register. Vol. 59, No. 59. 59 FR 14508-15413 (March 28, 1994). LexisNexis Academic Universe database (Congressional > Regulations > Federal Register).
*
National Institutes of Health, National Library of Medicine, Office of Outreach and Special Populations (OOPS), Division of Specialized Information Services. 2008 Overarching Themes of the Priorities for Research in Women’s Health. Bethesda, MD: OOPS, 2008
*
National Institutes of Health, Office of Extramural Research. Inclusion of Women and Minorities As Participants In Research Involving Human Subjects - Policy Implementation Page. [Bethesda, MD: NIH OER, 2007.
*
National Institutes of Health, Office of Extramural Research. NIH Guide for Grants and Contracts 1987;16(30), 1-6.
*
National Institutes of Health, Office of Research on Women’s Health. 2009 NIH Research Priorities for Women’s Health. [Bethesda, MD: NIH ORWH, 2009.]
*
National Institutes of Health, Office of Research on Women’s Health. Office of Research on Women’s Health: 2008 Research Priorities for Women’s Health. Bethesda, MD: NIH ORWH, 2008.
*
National Institutes of Health, Office of Research on Women's Health (ORWH). Outreach Documents [inclusion of women and minorities in clinical research]. Bethesda, MD: NIH ORWH. & Human Services
**
National Institutes of Health, Office of Research on Women's Health (ORWH). Outreach Notebook for the Inclusion, Recruitment, and Retention of Women and Minority Subjects in Clinical Research. NIH Publication No. 03-7036. Bethesda, MD: NIH, December 2002.
*
National Institutes of Health, Office of Research on Women's Health (ORWH). Outreach Frequently Asked Questions: Concerning the NIH Guidelines on the Inclusion of Women and Minorities in Clinical Research. Bethesda, MD: NIH,2003. [Includes information about preparing applications, proposals, and progress reports that conform to NIH policy and guidelines.]
*
National Institutes of Health, Office of Research on Women’s Health. Report of the National Institutes of Health: Opportunities for Research on Women’s Health, September 4-6, 1991, Hunt Valley, Maryland. NIH publication no. 92-3457 A. [Bethesda, MD]: NIH ORWH, 1992.
*
National Institutes of Health, Office of Extramural Research. Sex/Gender and Minority Inclusion in NIH Clinical Research: What Investigators Need to Know! [index and ppt link]. [Bethesda, MD: NIH,] November 21, 2002.
*
National Institutes of Health, Office of Research on Women’s Health, Advisory Committee on Research on Women’s Health. Office of Women’s Health and NIH support for research on women’s health issues: Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2003 & 2004. [Bethesda, MD: NIH ORWH, 2005].
*
National Institutes of Health, Office of Research on Women’s Health, Task Force on the Recruitment and Retention of Women in Clinical Studies. Science Meets Reality: Recruitment and Retention of Women in Clinical Studies, and the Critical Role of Relevance, January 6-9, 2003: A report of the Task Force sponsored by the NIH Office of Women’s Health. NIH Pub No. 03-5403. Rockville, MD: NIH, 2003.
*
National Institutes of Health, Office of Research on Women's Health; and Food and Drug Administration, Office of Women's Health. The Science of Sex and Gender in Human Health Online Course Web Site. Bethesda, MD; Rockville, MD: NIH ORWH; FDA OWH.
**
Pinn VW. Introduction: Revisiting the NIH research agenda on women’s health for the 21st century: a collaboration between NIH and the broader women’s health community. p. v-vii. In: National Institutes of Health. Agenda for Research on Women’s Health for the 21st Century: A Report of the Task Force on the NIH Women’s Health Agenda for the 21st Century: Executive Summary. Vol. 1. [Bethesda, MD]: National Institutes of Health, Office of the Director, Office of Research on Women's Health, 1999. p. 1-7. NIH publication no. 99-4385-90. (Note: There are links from the Publications section under Research Agenda to the complete 8 volume report.)
*
Simon, V. R., et al.; The Society for Women's Health Research. National Institutes of Health: Intramural and extramural support for research on sex differences, 2000-2003. Scientific Report Series: Understanding the biology of sex differences. Washington, DC: Society for Women's Health Research, 2005. 11 p. pdf
*
U.S. Department of Health and Human Services, Health Resources and Services Administration. Women's Health USA 2008, 7th ed. Rockville, Maryland: U.S. HHS, 2006. D: HHS, 2006.**
**
U.S. Department of Health & Human Services (HHS), Office of Research on Women's Health (ORWH). Outreach Frequently Asked Questions [includes information about preparing applications, proposals, and progress reports that conform to NIH policy and guidelines]. {Bethesda, MD]: HHS, 2003.
*
U.S. Department of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality. Translating Research into Practice (TRIP) – II. AHRQ Pub. No. 01-P017. March 2001. Rockville, MD: AHSQ, 2001.
*
U.S. Food and Drug Administration. General Considerations for the Clinical Evaluation of Drugs. [FDA Bureau of Drugs clinical guidelines.] DHEW publication; no. (FDA) 77-3040. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Food and Drug Administration, 1977.
*
U.S. Food and Drug Administration. Guidance for Industry on the Collection of Race and Ethnicity Data in Clinical Trials; Availability, Notice. Rockville, MD: FDA CBER: September 2005.
*
U.S. Food and Drug Administration. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. Notices. Federal Register. Vol. 58, No. 139. 58 FR 39406 (July 22, 1993). LexisNexis Academic Universe database (Congressional > Regulations > Federal Register).
*
U.S. Food and Drug Administration. Investigational New Drug Applications and New Drug Applications. Rules and Regulations. Federal Register. Vol. 63; No. 28. Gender-Specific Medicine (article) 1963 FR 6854 (February 11, 1998). [Rockville, MD: FDA, 1998. LexisNexis Academic Universe database (Congressional>Regulations>Federal Register).
*
U.S. Food and Drug Administration. Response to Congressional Request for 2002 Funding for Gender-based Research. Conference Action P.L. 107-76. [Rockville, MD: FDA], June 2002. pdf version
*
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Collection of Race and Ethnicity Data in Clinical Trials. Rockville, MD: FDA CBER: September 2005. pdf version
*
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Reviewer Guidance: Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review. Rockville, MD: FDA CDER: February 2005.
*
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment. [Rockville, MD: FDA CDER, CBER]: March 2005.
*
[U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.] Guideline for Industry: E6 Good Clinical Practice: Consolidated Guidance. [Rockville, MD: CDER, CBER]: April1996.
*
[U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.] Guideline for Industry: Structure and Content of Clinical Study Reports. [Rockville, MD: CDER, CBER]: July 1996.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Content and Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs and Biologics [Draft Guidance].
Rockville, MD: FDA CDER CBER: May 2000.
*
U.S. Food and Drug Administration, Center for Drug Evaluation and Research, FDAMA Women and Minorities Working Group. FDAMA Women and Minorities Working Group Report: Women and Minorities Guidance Requirements. [Rockville, MD: CDER]: July 20, 1998.
*
U.S. Food and Drug Administration, Center for Drug Evaluation and Research: Office of Special Health Issues, Office of International and Constituent Relations, & Office of the Commissioner. Women’s Participation in Clinical Trials and Gender-Based Labeling: A Review of New Molecular Entities Approved 1995-1999. Rockville, MD: CDER, 2001.
*
U.S. Food and Drug Administration, Office of Women's Health. 10 Years and Beyond. Rockville, MD: March 2006.
*
U.S. Food and Drug Administration, Office of Women’s Health. Demographic Information and Data Repository (DIDR) Information Warehouse. Rockville, MD: FDA OWH, [n.d.].
*
U.S. Food and Drug Administration, Office of Women's Health. Gender Studies in Product Development: Scientific Issues and Approaches. Rockville, MD: November 1995.
**
U.S. Food and Drug Administration, Office of Women's Health. Protecting and Advancing Women's Health: 10 Years and Beyond ... . Rockville, MD: FDA, OWH, [2005?].
*
U.S. General Accounting Office. Drug safety: Most drugs withdrawn in recent years had greater health risks for women. Publication no. GAO-01-286R. Washington, D.C.: U.S. GAO. 2001.
*
U.S. General Accounting Office. Major Management: Challenges and Program Risks. Publication no. GAO-03-101. Washington, DC: U.S> GAO, 2003.
*
U.S. General Accounting Office. National Institutes of Health: Problems in Implementing Policy on Women’s Study Populations. Testimony. Publication no. GAO/T-HRD-90-38. Washington, DC: U.S. GAO, June 18 1990.
*
U.S. General Accounting Office. Women’s health: FDA needs to ensure more study of gender differences in prescription drug testing. Publication no. GAO/HRD-93-17. Washington, DC: U.S. GAO, 1992.
*
U.S. General Accounting Office. Women's Health: Women sufficiently represented in new drug testing, but FDA oversight needs improvement. Publication no. GAO-01-754. Washington, D.C.: U.S. GAO. 2001.
*
U.S. General Accounting Office. Women’s Health: NIH Has Increased its Efforts to Include Women in Research. Publication no. GAO/HEHS-00-96. Washington, DC: GAO, 2000.
*
U.S. General Accounting Office. Women’s Health: Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement. Publication no. GAO-01-754. Washington, DC: U.S. GAO, July 2001.
**
U.S. Public Health Service, Task Force on Women’s Health Issues. Women’s health: Report of the Public Health Service Task Force on Women’s Health Issues. Public Health Rep 1985;100:73-106. Rockville, MD: U.S. PHS, 1985.
*
U.S. General Accounting Office. Women's health information: HHS lacks an overall strategy. Publication no. GAO/T-HRD-92-51. Washington, D.C.: U.S. GAO. 1992.
*
*
